Remote Glucose Monitoring in Hospital Settings (REMOTE-CGM)
Diabetes Mellitus, Type 2, Hyperglycemia Stress, Hypoglycemia
About this trial
This is an interventional treatment trial for Diabetes Mellitus, Type 2 focused on measuring Inpatient diabetes, Real-time continuous glucose monitoring, Glucose sensors, Remote monitoring
Eligibility Criteria
Inclusion Criteria:
- Aged 18 years or older
- Diagnosed with Type 2 diabetes
- Currently receiving treatment with subcutaneous insulin alone, or in combination with oral glucose-lowering medication(s)
- At least one CBG level > 10mmol/l
- Have the ability to consent in English
Exclusion Criteria:
- Autoimmune type 1 diabetes
- Known or suspected allergy against insulin
- Current or planned pregnancy or breast feeding
- Current in-patient in intensive care unit
- Planned surgery during study period
- Any physical or psychological disease or medication(s) likely to interfere with the conduct of the study and interpretation of the study results, as judged by the study clinician.
- Likely discharge earlier than 72 hours
Sites / Locations
- Manchester Royal InfirmaryRecruiting
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
Real-Time CGM
Capillary blood glucose with masked CGM
This group will have a subcutaneous RT-CGM inserted by a member of the research team. CGM's low and high glucose alerts will be activated. The treating clinical team will be able to remotely monitor glucose data and be notified of low glucose alerts through the linked handset. Hyper- and hypo-glycemia management including insulin dose adjustments by the treating clinical team, will be guided by sensor glucose levels and trends according to written guidelines during the study. Glucose level during and post-hypoglycaemia treatment will be confirmed by capillary blood glucose (CBG) measurements (using the NovaStat® glucometer or similar CE-marked glucose meter).
This group will have their glucose monitored in hospital using the NovaStat® glucometer or similar CE-marked glucose meter) and insulin dose adjusted by the treating clinical team as per usual hospital guidelines. A masked subcutaneous CGM will be inserted by a member of the research team to collect glucose values (glucose values will not be displayed and no glucose alerts will be available). This will removed at the end of the study by the research team.